Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
In re: Nexium Antitrust
Case Number:
14-1522
Court:
Nature of Suit:
Companies
- Burlington Stores Inc.
- Giant Eagle Inc.
- International Brotherhood of Electrical Workers
- Ranbaxy
- Rite Aid Corp.
- Rochester Drug Cooperative Inc.
Sectors & Industries:
-
January 23, 2015
Nexium Ruling Offers Road Map For Pay-For-Delay Classes
The First Circuit's decision to uphold class certification in the Nexium pay-for-delay litigation despite the presence of some uninjured members in the group may be a hollow victory for the heartburn-drug purchasers after their recent loss at trial, but the ruling offers a boost for other plaintiffs as a bevy of antitrust class actions over pharmaceutical patent settlements forge ahead.
-
January 22, 2015
1st Circ. OKs Class Cert. In Nexium Pay-For-Delay Suit
The First Circuit on Wednesday upheld the certification of a class of indirect purchasers of Nexium in pay-for-delay litigation over the heartburn drug, ruling that the presence of a few uninjured members in the class didn't prevent certification.
-
December 22, 2014
Nexium Buyers Call Appeal Dismissal Bid 'Gamesmanship'
A group of Nexium buyers told the First Circuit on Friday that they didn't oppose AstraZeneca AB's bid to dismiss its class certification challenge in a pay-for-delay suit over the heartburn drug but warned that the drugmaker's claim that the suit was wrapped up was "mere gamesmanship."
-
December 11, 2014
AstraZeneca Drops 1st Circ. Row Over Nexium Class Cert.
AstraZeneca AB and three generic-drug producers asked the First Circuit on Wednesday to dismiss their bid to nix class certification in a suit over alleged pay-for-delay deals regarding the heartburn drug Nexium, just five days after a jury handed a victory to the pharmaceutical giant in the lower part of the case.